Literature DB >> 35962273

The S-Factor, a New Measure of Disease Severity in Spinocerebellar Ataxia: Findings and Implications.

Louisa P Selvadurai1, Susan L Perlman2, George R Wilmot3, Sub H Subramony4, Christopher M Gomez5, Tetsuo Ashizawa6, Henry L Paulson7, Chiadi U Onyike8, Liana S Rosenthal9, Haris I Sair10, Sheng-Han Kuo11, Eva-Maria Ratai12, Theresa A Zesiewicz13, Khalaf O Bushara14, Gülin Öz15, Cameron Dietiker16, Michael D Geschwind16, Alexandra B Nelson16, Puneet Opal17, Talene A Yacoubian18, Peggy C Nopoulos19, Vikram G Shakkottai20, Karla P Figueroa21, Stefan M Pulst21, Peter E Morrison22, Jeremy D Schmahmann23.   

Abstract

Spinocerebellar ataxias (SCAs) are progressive neurodegenerative disorders, but there is no metric that predicts disease severity over time. We hypothesized that by developing a new metric, the Severity Factor (S-Factor) using immutable disease parameters, it would be possible to capture disease severity independent of clinical rating scales. Extracting data from the CRC-SCA and READISCA natural history studies, we calculated the S-Factor for 438 participants with symptomatic SCA1, SCA2, SCA3, or SCA6, as follows: ((length of CAG repeat expansion - maximum normal repeat length) /maximum normal repeat length) × (current age - age at disease onset) × 10). Within each SCA type, the S-Factor at the first Scale for the Assessment and Rating of Ataxia (SARA) visit (baseline) was correlated against scores on SARA and other motor and cognitive assessments. In 281 participants with longitudinal data, the slope of the S-Factor over time was correlated against slopes of scores on SARA and other motor rating scales. At baseline, the S-Factor showed moderate-to-strong correlations with SARA and other motor rating scales at the group level, but not with cognitive performance. Longitudinally the S-Factor slope showed no consistent association with the slope of performance on motor scales. Approximately 30% of SARA slopes reflected a trend of non-progression in motor symptoms. The S-Factor is an observer-independent metric of disease burden in SCAs. It may be useful at the group level to compare cohorts at baseline in clinical studies. Derivation and examination of the S-factor highlighted challenges in the use of clinical rating scales in this population.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Disease progression; Natural history; Scale for the Assessment and Rating of Ataxia; Spinocerebellar ataxia

Year:  2022        PMID: 35962273     DOI: 10.1007/s12311-022-01424-1

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.648


  32 in total

1.  Evidence of oxidative stress and mitochondrial dysfunction in spinocerebellar ataxia type 2 (SCA2) patient fibroblasts: Effect of coenzyme Q10 supplementation on these parameters.

Authors:  Nanna Cornelius; Jonathan H Wardman; Iain P Hargreaves; Viruna Neergheen; Anne Sigaard Bie; Zeynep Tümer; Jørgen E Nielsen; Troels T Nielsen
Journal:  Mitochondrion       Date:  2017-03-03       Impact factor: 4.160

2.  The cerebellar cognitive affective/Schmahmann syndrome scale.

Authors:  Franziska Hoche; Xavier Guell; Mark G Vangel; Janet C Sherman; Jeremy D Schmahmann
Journal:  Brain       Date:  2018-01-01       Impact factor: 13.501

3.  Development of SARAhome , a New Video-Based Tool for the Assessment of Ataxia at Home.

Authors:  Marcus Grobe-Einsler; Arian Taheri Amin; Jennifer Faber; Tamara Schaprian; Heike Jacobi; Tanja Schmitz-Hübsch; Alhassane Diallo; Sophie Tezenas du Montcel; Thomas Klockgether
Journal:  Mov Disord       Date:  2021-01-12       Impact factor: 10.338

4.  Genetic risk factors for modulation of age at onset in Machado-Joseph disease/spinocerebellar ataxia type 3: a systematic review and meta-analysis.

Authors:  Eduardo Preusser de Mattos; Maiara Kolbe Musskopf; Vanessa Bielefeldt Leotti; Maria Luiza Saraiva-Pereira; Laura Bannach Jardim
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-10-18       Impact factor: 10.154

5.  Sensitivity of Volumetric Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy to Progression of Spinocerebellar Ataxia Type 1.

Authors:  Dinesh K Deelchand; James M Joers; Adarsh Ravishankar; Tianmeng Lyu; Uzay E Emir; Diane Hutter; Christopher M Gomez; Khalaf O Bushara; Christophe Lenglet; Lynn E Eberly; Gülin Öz
Journal:  Mov Disord Clin Pract       Date:  2019-07-10

6.  Plasma neurofilament light chain predicts cerebellar atrophy and clinical progression in spinocerebellar ataxia.

Authors:  Giulia Coarelli; Frederic Darios; Emilien Petit; Karim Dorgham; Isaac Adanyeguh; Elodie Petit; Alexis Brice; Fanny Mochel; Alexandra Durr
Journal:  Neurobiol Dis       Date:  2021-02-23       Impact factor: 5.996

7.  Genetic analysis of age at onset variation in spinocerebellar ataxia type 2.

Authors:  K P Figueroa; Hilary Coon; Nieves Santos; Luis Velazquez; Luis Almaguer Mederos; Stefan-M Pulst
Journal:  Neurol Genet       Date:  2017-05-15

8.  Computer mouse use captures ataxia and parkinsonism, enabling accurate measurement and detection.

Authors:  Krzysztof Z Gajos; Katharina Reinecke; Mary Donovan; Christopher D Stephen; Albert Y Hung; Jeremy D Schmahmann; Anoopum S Gupta
Journal:  Mov Disord       Date:  2019-11-07       Impact factor: 10.338

9.  Natural history of most common spinocerebellar ataxia: a systematic review and meta-analysis.

Authors:  Alhassane Diallo; Heike Jacobi; Sophie Tezenas du Montcel; Thomas Klockgether
Journal:  J Neurol       Date:  2020-04-07       Impact factor: 4.849

10.  Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study.

Authors:  Tetsuo Ashizawa; Karla P Figueroa; Susan L Perlman; Christopher M Gomez; George R Wilmot; Jeremy D Schmahmann; Sarah H Ying; Theresa A Zesiewicz; Henry L Paulson; Vikram G Shakkottai; Khalaf O Bushara; Sheng-Han Kuo; Michael D Geschwind; Guangbin Xia; Pietro Mazzoni; Jeffrey P Krischer; David Cuthbertson; Amy Roberts Holbert; John H Ferguson; Stefan M Pulst; S H Subramony
Journal:  Orphanet J Rare Dis       Date:  2013-11-13       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.